Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. by Howarth, D. J. et al.
British Journal ofCancer(1997) 75(11), 1646-1651
© 1997 Cancer Research Campaign
lmmunohistochemical localization of prostate-specific
antigen in benign and malignant breast tissues
DJC Howarth, IB Aronson and EP Diamandis
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Departments of Pathology and Clinical Biochemistry, University of Toronto,
Toronto, Ontario, Canada
Summary Prostate-specific antigen (PSA), a glycoprotein initially thought to be produced only by the epithelial cells of the prostate, has
recently been found in 30% of female breast tumours using immunofluorometry. Our aim was to localize PSA immunohistochemically in a
selected group of 27 paraffin-embedded breast tissues. A scoring system was developed for the histological assessment of PSA positivity
within the breast tissue. One pathologist (DH) scored, classified and graded all tumours. Site-specific PSA staining was noted in the histology
slides. Intense staining was identified in apocrine metaplasia and within the lining ductal epithelium of cystically dilated ducts. The epithelium
in lesions of sclerosing adenosis was also frequently positive for PSA staining. Hyperplastic ductal epithelium (especially of mild degree)
occasionally stained positive, as did normal breast ducts. Better differentiated tumours showed PSA staining [e.g. mucinous carcinoma
(colloid)]. If an infiltrating duct carcinoma showed staining for PSA, adjacent intraductal carcinoma was also noted to stain positively, if
present.
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Prostate-specific antigen (PSA) is aglycoprotein initially isolatedby
Wang et al (1979). It is responsible for liquefying the clot formed
immediately following ejaculation (Lilja et al, 1987) and has been
localized in the cytoplasmic granules and vesicles in prostatic
epithelial cells (Armbruster, 1993). PSA was originally described as
being produced exclusively by prostatic tissue and is widely used as
a tumour marker for patients with prostatic carcinoma (Armbruster,
1993). Although it is extremely uncommon to detect PSA in
tumours other than those of prostatic origin, current studies have
reported findings of PSA in 30% of female breast tumours using
immunofluorometry (Diamandis et al, 1994; Yu et al, 1994a, b).
Receptors for progestin, oestrogen and androgen have been exhib-
ited in breast tumours, and studies have shown that the presence of
PSA is associated with these receptors (Yu et al, 1994b).
PSA in normal breast tissue and tumours has not as yet been
localized immunohistochemically. Our aim was to localize PSA by
immunohistochemistry in 27 breast tissues selected to be either
positive or negative for PSA by immunofluorometry.
MATERIALS AND METHODS
Twenty-seven female breast tissues were chosen from a group that
had been previously assayed for PSA immunofluorometrically
(Diamandis et al, 1994). Representative slides were requested from
the various hospitals which had supplied the initial tissues. These
included 21 cases ofinfiltrating duct carcinoma, two cases ofinfil-
trating lobular carcinoma, one mucinous (colloid) carcinoma, one
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fibroadenoma, one papillary intraductal carcinoma and one severe
atypical epithelial hyperplasia. In these sections, there were also
the following accompanying abnormalities: ten adjacent intra-
ductal carcinomas and 16 adjacent epithelial hyperplasias.
Immunohistochemical staining for PSA was carried out on
formalin-fixed, paraffin-embedded tissue using the avidin-biotin
peroxidase complex method. The type of tumour was recorded
from the pathology reports and assessed by the pathologist (DH).
Immunohistochemical staining was scored by the pathologist
(DH) without knowledge of the immunofluorometric data, as
follows: 0, none; 1+, focal faint staining (<50% of cells); 2+,
diffuse faint (> 50% ofcells); 3+, focal positive; 4+, diffuse posi-
tive. The scoring system was applied to each of the individual
components of the lesion (described in the Table). This method
takes into account the heterogeneity of the tumours sampled. The
presence ofintraductal carcinoma was noted. The degree ofhyper-
plasia was noted as mild, moderate or severe, if present.
Fibrocystic changes, including dilatation of ducts, apocrine meta-
plasia, sclerosing adenosis and papillomatosis, were recorded and
staining noted. Normal breast lobules and their staining pattern
were also noted.
Immunohistochemistry of PSA
The tissue sections were deparaffinized in xylol and hydrated
through a graduated series of alcohols. Endogenous peroxidase
activity was blocked by 3% hydrogen peroxide. The tissue was
immersed in a pepsin digestive enzyme at 37°C for 10 min. A 5%
universal tissue conditioner (Biomeda) was applied at room
temperature for 10 min to block any non-specific binding. At
37°C, sections were incubated with prediluted polyclonal rabbit
anti-human PSA antibody (DAKO Cat. no. A562, 1:200 dilution)
for 1 h, then 20 min with a universal secondary antibody
(Biomeda), followed by an autoprobe III peroxidase reagent
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(Biomeda) for another 20 min. After each step, a brief wash in
buffer solution was performed. Aminoethyl carbazole with
hydrogen peroxide served as the chromogenic substrates and slides
were counterstained with haematoxylin. Tissue from prostate was
used as a positive control, and the primary antibody was omitted
and replaced with non-immune serum to serve as the negative
control.
Immunofluorometric analysis
Breast tumour tissue obtained at surgery was pulverized and
cytosolic fractions prepared as described previously (Diamandis et
al, 1994). PSA in breast tumour cytosols was assayed using an
immunofluorometric procedure (Yu and Diamandis, 1993).
Tumours containing more than 0.03 ng of PSA per mg of total
protein were considered positive for PSA.
RESULTS
The results are shown in the Table and Figures 1-12. In our study,
PSA was found to be present intracytoplasmically within both
benign and malignant lesions. Of the 21 infiltrating duct carci-
nomas, 13 stained at least faintly positive for PSA. Eight out of21
stained intensely positive either focally or diffusely for prostate-
specific antigen. One outoftwo lobularcarcinomas stained focally
intensely positive for PSA.
The tissue with the highest PSA level by immunofluorometric
analysis (49 ng mg-' total protein) was a fibroadenoma with adja-
cent fibrocystic changes. The proliferating epithelium in the
fibroadenoma as well as the cysts in the fibrocystic changes both
exhibited a significant degree ofPSA staining immunohistochem-
ically. Apocrine metaplastic epithelium stained intensely positive
for PSA.
Figure 1 Immunohistochemical staining for prostate-specific antigen in Figure 2 Immunohistochemical staining for prostate-specific antigen in
normal breast ducts (original magnification x 400), case 24 cystic dilatation of ducts and apocrine metaplasia (orginal magnification x
100), case 16
Figure 3 Immunohistochemical staining for prostate-specific antigen in Figure 4 Immunohistochemical staining for prostate-specific antigen in
apocrine metaplastic epithelium (original magnification x 250), case 16 sclerosing adenosis (original magnification x 250), case 16
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Figure 5 Immunohistochemical staining for prostate-specific antigen in mild Figure 6 Immunohistochemical staining for prostate-specific antigen in
epithelial hyperplasia (original magnification x 250), case 3 moderate epithelial hyperplasia and papillomatosis (original magnification x
400), case 19
Figure 7 Immunohistochemical staining for prostate-specific antigen in
severe epithelial hyperplasia (original magnification x 250), case 19
Figure 9 Immunohistochemical staining for prostate-specific antigen in
infiltrating duct carcinoma (original magnification x 100), case 16
Figure 8 Immunohistochemical staining for prostate-specific antigen in
intraductal carcinoma with comedonecrosis (original magnification x 100),
case 26
Figure 10 Immunohistochemical staining for prostate-specific antigen in
infiltrating duct carcinoma (original magnification x 250), case 16
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Figure 11 Immunohistochemical staining for prostate-specific antigen in Figure 12 Immunohistochemical staining for prostate-specific antigen in
infiltrating ductcarcinoma, mucinous area (onginal magnification x250), case 12 fibroadenoma (original magnification x 250), case 27
DISCUSSION
Our series of 27 breast tissues was selected from a large series of
breast tumours previously used to study PSA expression by
immunofluorometric analysis (Diamandis et al, 1994). The single
criterion that we have used for selection was PSA content by
immunofluorometry; 12 cases were negative for PSA, while the
remainder were positive for PSA (PSA 2 2.5 ng mg-' total
cytosolic protein).
PSA staining was seen immunohistochemically to be present
intracytoplasmically. There was often a concentration at the
luminal surface that was seen most markedly in benign cysts and
apocrine metaplastic epithelium.
We did not observe acorrelation between immunohistochemical
results ofPSA staining with immunofluorometric analysis ofPSA.
Some of the tissues positive for PSA by immunofluorometry did
not have a correlate within the tissue section assayed, and some of
the PSA-negative tissues had lesions in which there were regions
ofsignificant staining by immunohistochemistry. This discrepancy
could be accounted for by sampling, as the portion of tumour
assayed (left over from steroid hormone receptor analysis) was not
the portion studied by immunohistochemistry. Also, the slight
differences in fixation among tissue from the contributing hospi-
tals may introduce variability with the immunohistochemical
analysis.
Despite this, a few trends were noted:
1. The PSA level by immunofluorometry was often higher ifthe
tumour demonstrated PSA staining immunohistochemically.
2. The PSA level assayed was often higher ifthe hyperplastic
epithelium or in situ carcinoma was positive by immunohisto-
chemistry.
3. In virtually all ofthe specimens, cystically dilated ducts and
apocrine metaplastic epithelium showed a significant amount
ofstaining. The epithelium ofsclerosing adenosis was also
frequently positive.
4. Benign breast ducts were occasionally seen to stain positive
for PSA, as did mild hyperplasia ofductal epithelium.
PSA was initially proposed to be an organ-specific marker
(Berger, 1993). However, PSA has been detected in female
Skene's gland (Wemett et al, 1992) and male salivary gland
neoplasms (Van Krieken, 1993). Normal female breast also
produces PSA (Yu et al, 1995), and during pregnancy PSA is
secreted in human milk (Yu and Diamandis, 1995). PSA has been
demonstrated using highly sensitive immunofluorometric proced-
ures in approximately 30% of female breast tumours (Diamandis
et al, 1994; Yu et al, 1994a, b), although specific histological types
were not mentioned. As this technique does not allow for localiza-
tion of the signal, heterogeneity of tumorous and non-tumorous
breast tissue cannot be assessed.
The data presented here are in accord with previous studies that
have shown PSA expression in the normal female breast (Yu et al,
1995), in fibrocystic tissue (Yu et al, 1996), in breast tumours
(Diamandis et al, 1994) and breast cancer cell lines (Yu et al,
1994c). The biological function of PSA in the female breast is
currently unknown (Diamandis and Yu, 1995).
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